{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:25:58Z","timestamp":1788387958937,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,10]],"date-time":"2017-07-10T00:00:00Z","timestamp":1499644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.clinthera.2017.06.006","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T23:30:28Z","timestamp":1498692628000},"page":"1639-1648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Vigabatrin Lacks Proarrhythmic Potential: Results from a Thorough QT\/QTc Study in Healthy Volunteers"],"prefix":"10.1016","volume":"39","author":[{"given":"Dwain","family":"Tolbert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihor","family":"Bekersky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2017.06.006_bib1","series-title":"Sabril [package insert]","year":"2013"},{"key":"10.1016\/j.clinthera.2017.06.006_bib2","series-title":"Vigabatrin [summary of product characteristics]","year":"1999"},{"key":"10.1016\/j.clinthera.2017.06.006_bib3","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","author":"Roden","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.06.006_bib4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/med.20019","article-title":"QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development","volume":"25","author":"Recanatini","year":"2005","journal-title":"Med Res Rev"},{"key":"10.1016\/j.clinthera.2017.06.006_bib5","year":"2005","journal-title":"The Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs"},{"key":"10.1016\/j.clinthera.2017.06.006_bib6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1476-5381.2009.00487.x","article-title":"The thorough QT\/QTc study 4 years after the implementation of the ICH E14 guidance","volume":"159","author":"Darpo","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2017.06.006_bib7","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eplepsyres.2016.12.011","article-title":"Determining factors of electrocardiographic abnormalities in patients with epilepsy: a case-control study","volume":"129","author":"de Sousa","year":"2017","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.clinthera.2017.06.006_bib8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1528-1167.2009.02330.x","article-title":"Pathologic cardiac repolarization in pharmacoresistant epilepsy and its potential role in sudden unexpected death in epilepsy: a case-control study","volume":"51","author":"Surges","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2017.06.006_bib9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.0954-6820.1920.tb18266.x","article-title":"Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken (The duration of systole in an electrocardiogram in normal people and in those with heart disease)","volume":"53","author":"Fridericia","year":"1920","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.clinthera.2017.06.006_bib10","first-page":"353","article-title":"An analysis of time relations in electrocardiograms","volume":"7","author":"Bazett","year":"1920","journal-title":"Heart"},{"key":"10.1016\/j.clinthera.2017.06.006_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/ane.12416","article-title":"Lacosamide cardiac safety: a thorough QT\/QTc trial in healthy volunteers","author":"Kropeit","year":"2015","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.clinthera.2017.06.006_bib12","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2125.2008.03250.x","article-title":"Lamotrigine does not prolong QTc in a thorough QT\/QTc study in healthy subjects","volume":"66","author":"Dixon","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2017.06.006_bib13","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/0091270010391789","article-title":"Evaluation of eslicarbazepine acetate on cardiac repolarization in a thorough QT\/QTc study","volume":"52","author":"Vaz-Da-Silva","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2017.06.006_bib14","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.eplepsyres.2015.04.010","article-title":"Lack of effect of perampanel on QT interval duration: results from a thorough QT analysis and pooled partial seizure Phase III clinical trials","volume":"114","author":"Yang","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.clinthera.2017.06.006_bib15","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clinthera.2008.02.002","article-title":"Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study","volume":"30","author":"Hulhoven","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2017.06.006_bib16","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/00003088-199223040-00003","article-title":"Olive G. Vigabatrin. Clinical pharmacokinetics","volume":"23","author":"Rey","year":"1992","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2017.06.006_bib17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2125.1990.tb03772.x","article-title":"Pharmacokinetics of the individual enantiomers of vigabatrin (gamma-vinyl GABA) in epileptic children","volume":"30","author":"Rey","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2017.06.006_bib18","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/bcp.12884","article-title":"Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians","volume":"81","author":"Hasunuma","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2017.06.006_bib19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12941-016-0150-4","article-title":"Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin","volume":"15","author":"Kocsis","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.clinthera.2017.06.006_bib20","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1128\/AAC.44.10.2600-2603.2000","article-title":"Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers","volume":"44","author":"Lubasch","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2017.06.006_bib21","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/bcp.12684","article-title":"Moxifloxacin-induced QTc interval prolongations in healthy male Japanese and Caucasian volunteers: a direct comparison in a thorough QT study","volume":"80","author":"Morganroth","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2017.06.006_bib22","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/j.1552-4604.1993.tb04688.x","article-title":"Pharmacokinetics of vigabatrin following single and multiple oral doses in normal volunteers","volume":"33","author":"Hoke","year":"1993","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2017.06.006_bib23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1146\/annurev.me.36.020185.002225","article-title":"Elimination half-life of drugs: value and limitations","volume":"36","author":"Greenblatt","year":"1985","journal-title":"Annu Rev Med"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2017.06.006_bib24","first-page":"S7","article-title":"Pharmacology and clinical pharmacology of vigabatrin","author":"Richens","year":"1991","journal-title":"J Child Neurol"},{"key":"10.1016\/j.clinthera.2017.06.006_bib25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/00007691-200308000-00007","article-title":"Serum concentrations and effects of gabapentin and vigabatrin: observations from a dose titration study","volume":"25","author":"Lindberger","year":"2003","journal-title":"Ther Drug Monit"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2017.06.006_bib26","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1111\/j.1365-2125.1989.tb03455.x","article-title":"Experimental studies of the influence of vigabatrin on the GABA system","volume":"27","author":"Gram","year":"1989","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817307300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817307300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T20:05:15Z","timestamp":1575662715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291817307300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0149291817307300"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.06.006","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vigabatrin Lacks Proarrhythmic Potential: Results from a Thorough QT\/QTc Study in Healthy Volunteers","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}